41 results on '"Darcy, K.M."'
Search Results
2. Characterization of isogenic ovarian cancer cell line models of acquired resistance to the clinical ATR inhibitor AZD6738
3. Use of a clinical score to predict chemotherapy response in stage I mucinous ovarian cancers
4. The survival advantage of adjuvant chemoradiotherapy in surgically managed patients with FIGO stages I-III uterine carcinosarcoma treated in Commission on Cancer®-accredited facilities
5. Proteomic evaluation of the fallopian tube: Insight into the pathogenesis of serous ovarian cancer
6. Impact of histology on disparities in survival between non-Hispanic black and non-Hispanic white women with epithelial ovarian cancer in Commission on Cancer®-accredited facilities
7. Age matters when predicting overall survival benefit of combined chemotherapy and radiation versus radiation alone in high risk endometrial cancer: A study of 20,000 women using PORTEC-3 criteria
8. Racial disparities in cancer-specific survival between 1973 and 2015 persist for uterine cancer and are growing for breast, ovarian and cervical cancer
9. Not immune from disparity: Two decades of racial minority participation in immunotherapy trials for breast and gynecologic cancers
10. Survival trends in gynecologic malignancies display modest progress and persistent challenges: An investigation of future opportunities
11. Factors to explain racial disparity in survival for women with uterine cancer: Further investigations by histologic subtype
12. Biomarker panel for early detection of endometrial cancer in the prostate, lung, colorectal, and ovarian cancer screening trial
13. Survival in elderly patients with vulvar cancer: A National Cancer Database study
14. Treatment and survival in elderly women with gynecologic cancer not inferior with Medicare versus private insurance: A National Cancer Database investigation
15. The contributory factors to racial disparity in survival varied in uterine versus ovarian carcinosarcoma: A National Cancer Database investigation
16. Tumors from ovarian cancer patients receiving neoadjuvant chemotherapy have unique protein profiles that associate with volume of residual disease after interval debulking surgery
17. Histology matters in developing a framework for explaining racial disparity in cervical cancer survival
18. Trends in uterine cancer incidence in the United States and Asian countries: A population analysis of 576,558 of women
19. Racial disparities in incidence and mortality in adenocarcinoma or adenosquamous carcinoma compared with squamous cell carcinoma of the cervix
20. Risk stratification in serous ovarian cancer using a classifier based on 30 transcripts
21. Impact of age at diagnosis on racial disparities in endometrial cancer patients
22. GOG 8035: Nuclear BRCA1 loss may identify a poor prognostic subgroup of women with locally advanced cervical cancer treated with cisplatin-based chemoradiation: An NRG Oncology study
23. Disparities in the survival trends in epithelial ovarian cancer patients in the United States
24. CTNNB1 predicts better progression-free survival in endometrioid endometrial cancer patients treated with chemotherapy
25. Surrogates of progression-free survival in endometrial cancer patients: An evaluation of necrosis and other measures of tissue composition
26. Mutations and transcript expression of maternal embryonic leucine zipper kinase in endometrial cancer patients
27. MS7 a transcript-based diagnostic classifier for metastatic disease and worse progression-free survival in endometrioid endometrial cancer patients
28. Interim analysis of a phase I/IIA trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
29. Racial differences in molecular subtypes between black and white patients with endometrial cancer
30. Proteogenomic alterations in black endometrioid endometrial cancer patients correlate with poor disease outcome
31. Racial and ethnic outcome differences in the top five women’s cancers: A harmonized Surveillance, Epidemiology, and End Results study for diagnoses from 2000-2014
32. Nestin: A biomarker of aggressive uterine cancers
33. Clinical assessments of MELK immunohistochemical expression in uterine cancer patients: A Gynecologic Cancer Center of Excellence study
34. A cost-effectiveness analysis of the AURELIA trial: Bevacizumab and paclitaxel offer a promising clinical and economic combination for platinum-resistant ovarian cancer
35. FIGO staging criteria is a meaningful clinical threshold for evaluating molecular signatures in serous ovarian cancer patients
36. Progestins and vitamin D inhibit CYP24A1 in vivo in ovarian cancer cell xenografts
37. Progestins inhibit calcitriol-induced CYP24A1 in endometrial and ovarian cancer cells
38. Interim analysis of a phase I/IIA trial assessing E39 + GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients
39. Progestins and vitamin D inhibit CYP24A1 in vivo in ovarian cancer cell xenografts
40. FIGO staging criteria is a meaningful clinical threshold for evaluating molecular signatures in serous ovarian cancer patients
41. Progestins inhibit calcitriol-induced CYP24A1 in endometrial and ovarian cancer cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.